The brain α7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: Studies with DMXBA (GTS-21)

Behavioural Brain Research

Volumn 113, Issue 1-2, 2000, Pages 169-181

  Kem, William R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

7 Nicotinic receptor; Alzheimer's dementia; Anabaseine; Cognition; GTS 21

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; ALPHA BUNGAROTOXIN; AMYLOID BETA PROTEIN; NICOTINIC RECEPTOR; RECEPTOR SUBTYPE; RECEPTOR SUBUNIT; 3-(2,4-DIMETHOXYBENZYLIDENE)ANABASEINE; ALPHA-BUNGAROTOXIN RECEPTOR; BENZYLIDENE DERIVATIVE; BUNGAROTOXIN RECEPTOR; NICOTINIC AGENT; PYRIDINE DERIVATIVE;

ALZHEIMER DISEASE; ARTICLE; BRAIN CORTEX; CLINICAL TRIAL; COGNITION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TARGETING; GABAERGIC SYSTEM; HUMAN; INTERNEURON; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR DOWN REGULATION; ANIMAL; DRUG EFFECT; FEMALE; HIPPOCAMPUS; MALE; MOUSE; NEUROPSYCHOLOGICAL TEST; RABBIT; RAT; REVIEW;

ALZHEIMER DISEASE; ANIMALS; BENZYLIDENE COMPOUNDS; CEREBRAL CORTEX; CLINICAL TRIALS, PHASE I; FEMALE; HIPPOCAMPUS; HUMANS; MALE; MICE; NEUROPSYCHOLOGICAL TESTS; NICOTINIC AGONISTS; PYRIDINES; RABBITS; RATS; RECEPTORS, NICOTINIC;

EID: 0033626286     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-4328(00)00211-4     Document Type: Article

References (78)

1. Akaike A., Tamura Y., Yokota T., Shimohama Sh., Kimura J. Nicotine-induced protection of cultured cortical neurons against N-methyl-D-aspartate receptor-mediated glutamate cytotoxicity. Brain Res. 644:1994;181-187.
2. Alkondon M., Pereira E.F.R., Cortes W.S., Maelicke A., Albuquerque E.X. Choline is a selective agonist of α7 nicotinic acetylcholine receptors in rat brain neurons. Eur. J. Neurosci. 9:1997;2734-2742.
3. Arendash G.W., Sengstock G.J., Sanberg R., Kem W.R. Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res. 674:1995;252-259.
4. Azuma R., Minami Y., Satoh T. Simultaneous determination of GTS-21 and its metabolite in rat plasma by high-performance liquid chromatography using solid-phase extraction. J. Chromatogr. 686:1996;229-234.
5. Azuma R., Komuro H., Korsch B.H., Andre J.C., Onnagawa O., Black S.R., Matheews J.M. Metabolism and disposition of GTS-21, a novel drug for Alzheimer's disease. Xenobiotics. 29:1999;747-762.
6. Barrantes G.E., Rogers A.T., Lindstrom J., Wonnacott S. α-Bungarotoxin binding sites in rat hippocampal and cortical cultures: initial characterisation, colocalisation with α7 subunits and up-regulation by chronic nicotine treatment. Brain Res. 672:1995;228-236.
7. Benowitz N.L., Porchet H., Jacob P. Pharmacokinetics, metabolism, and pharmacodynamics of nicotine. Wonnacott S., Russell M.A.H., Stolerman I.P. Nicotine Psychopharmacology: Molecular, Cellular, and Behavioral Aspects. 1990;112-157 Oxford University Press, Oxford, UK.
8. Bjugstad K.B., Mahnir V.M., Kem W.R., Arendash G.W. Long-term treatment with GTS-21 or nicotine enhances water maze performance in aged rats without affecting the density of nicotinic receptor subtypes in neocortex. Drug Dev. Res. 39:1996;19-28.
9. Briggs C.A., McKenna D.G., Piattoni-Kaplan M. Human α7 nicotinic acetylcholine receptor responses to novel ligands. Neuropharmacy. 34:1995;583-590.
10. Briggs C.A., Anderson D.J., Brioni J.D., Buccafusco J.J., Buckley M.J., Campbell J.E., Decker M.W., Donnelly-Roberts D., Elliott R.L., Gopalakrishan M., Holladay M.W., Hui Y.-H., Jackson W.J., Kim D.J.B., Marsh K.C., O'Neil A., Prendergast M.A., Ryther K.B., Sullivan J.P., Arneric S.P. Functional characterization of the novel neuronal nicotinic acetylcholine receptor ligand GTS-21 in vitro and in vivo. Pharmacol. Biochem. Behav. 57:1997;231-241.
11. Buisson B., Gopalakrishnan M., Arneric S.P., Sullivan J.P., Bertrand D. Human α4-β2 neuronal nicotinic acetylcholine receptor in HEK 293 cells: a patch-clamp study. J. Neurosci. 16:1996;7880-7891.
12. Cuevas J., Berg D.K. Mammalian nicotinc receptors with α7 subunits that slowly desensitize and rapidly recover from α-bungarotoxin blockade. J. Neurosci. 18:1998;8228-8235.
13. Davies P., Feisullin S. Postmortem stability of α-bungarotoxin binding sites in mouse and human brain. Brain Res. 216:1981;449-454.
14. Decker M.W., Brioni J.D., Bannon A.W., Arneric S.P. Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics. Life Sci. 56:1995;545-570.
15. 125K] α-Bungarotoxin receptor subtypes. Mol. Pharmacol. 47:1995;164-171.
16. Delbono O., Gopalakrishnan M., Renganathan M., Monteggia L.M., Messi M.L., Sullivan J.P. Activation of the recombinant human α7 nicotinic acetylcholine receptor significantly raises intracellular free calcium. J. Pharm. Exp. Ther. 280:1997;428-438.
17. Donnelly-Roberts D.L., Xue I.C., Arneric S.P., Sullivan J.P. In vitro neuroprotective properties of the novel cholinergic channel activator (ChCA), ABT-418. Brain Res. 719:1996;36-44.
18. Felix R., Levin E.D. Nicotinic antagonist administration into the ventral hippocampus and spatial working memory in rats. Neuroscience. 81:1997;1009-1077.
19. Finkbeiner S. Calcium-mediated gene expression: mechanism for neuronal plasticity and survival. The Neuroscientist. 1:1995;317-320.
20. Flores C.M., Davila-Garcia I., Ulrich Y.M., Kellar K.J. Differential regulation of neuronal nicotinic receptor binding sites following chronic nicotine administration. J. Neurosci. 69:1997;2216-2219.
21. Franklin J.L., Johnson E.M. Jr. Suppression of programmed neuronal death by sustained elevation of cytoplasmic calcium. Trends Neurosci. 15:1992;501-508.
22. Frazier C.J., Buhler A.V., Weiner J.L., Dunwiddie T.V. Synaptic potentials mediated via α-bungarotoxin-sensitive nicotinic acetylcholine receptors in rat hippocampal interneurons. J. Neurosci. 18:1998;8228-8235.
23. Fujita T., Nakajima M., Soeda Y., Yamamoto I. Physichochemical properties of biological interest and structure of nicotine and its related compounds. Pest. Biochem. Physiol. 1:1971;151-162.
24. Gioanni Y., Rougeot C., Clarke P.B.S., Lepouse C., Thierry A.M., Vidal C. Nicotinic receptors in the rat prefrontal cortex: increase in glutamate release and facilitation of mediodorsal thalamo-cortical transmission. Eur. J. Neurosci. 11:1999;18-30.
25. Gopalakrishnan M., Delbono O., Molinari E.J., Renganathan M., Messi L., Arneric S.P., Sullivan J.P. Regulation of recombinant human α7 nicotinic receptors by activator and antagonist ligands. Soc. Neurosci. Abstr. 603:1996;18.
26. Gray R., Rajan A.S., Radcliffe K.A., Yakehiro M., Dani J.A. Hippocampal synaptic transmission enhanced by low concentrations of nicotine. Nature. 383:1996;713-716.
27. Gurley D.A., Lanthorn T.H. Nicotinic agonists competitively antagonize serotonin at mouse 5-HT3 receptors expressed in Xenopus oocytes. Neurosci. Lett. 247:1998;107-110.
28. Hunter B.E., DeFiebre C.M., Papke R.L., Kem W.R., Meyer E.M. A novel nicotinic agonist facilitates induction of long-term potentiation in the rat hippocampus. Neurosci. Lett. 168:1994;130-134.
29. Kasahara N, Azuma R, Yamamoto J, Matsuura N. Mnemonic effects of GTS-21 and its 4-OH metabolite on scopolamine-induced deficits in passive avoidance behavior in rat, Proc. 6th Intern. Conf. Alzh. Dis., Amsterdam, 1998 (Abstr. 1082).
30. Kem W.R., Mahnir V.M., Lin B. Interaction of DMXB (GTS-21), a cognition-enhancing compound with cholinergic receptors. Soc. Neurosci. Abstr. 20:1994;1134.
31. Kem W.R., Mahnir V.M., Lin B., Prokai-Tartrai K. Two primary GTS-21 metabolites are potent partial agonists at α7 nicotinic receptors expressed in the Xenopus oocyte. Soc. Neurosci. 22:(Abstr. 268.7):1996;110.
32. Kem W.R., Mahnir V.M., Papke R., Lingle C. Anabaseine is a potent agonist upon muscle and neuronal α-bungarotoxin sensitive nicotinic receptors. J. Pharmacol. Exp. Ther. 283:1997;979-992.
33. Kem W.R. Alzheimer's drug design based upon an invertebrate toxin (anabaseine) which is a potent nicotinic receptor agonist. Invert. Neurosci. 3:1997;251-259.
34. Kihara T., Shimohama S., Sawada H., Kimura J., Kume T., Kochiyama H., Maeda T., Akaike A. Nicotinic receptor stimulation protects neurons against B-amyloid toxicity. Ann. Neurol. 42:1997;159-163.
35. Kitagawa H., Takenouchi T., Wesnes K., Kramer W., Clody D.E. Phase 1 studies of GTS-21 to assess the safety, tolerability, PK and effects on measures of cognitive function in normal volunteers, Proc. 6th Intern. Conf. Alzheim. Dis., Amsterdam, 1998 (Abstr. 765). Neurobiol. Aging. 19:1998;S182.
36. Kasten M.R., Pidoplichko V.I., Broide R.S., Goldner F.G., Patrick J.W., Dani J.A. Midbrain dopaminergic neurons possess α7-containing nicotinic receptors. Soc. Neurosci. 24:(Abstr. 331.4):1998;831.
37. Li Y, Papke RL, He Y-J, Millard WJ, Meyer EM. Characterization of the neuroprotective and toxic effects of α7 nicotinic receptor activation in PC12 cells. Brain Res 1999;830:218-225.
38. Lindstrom J. Neuronal nicotinic acetylcholine receptors. Narahashi T. Ion Channels. 1996;377-450 Plenum Press, New York.
39. Machu T, Strahlendorf J, Kem WR. Nicotinic receptor ligands antagonize 5-HT3 receptors expressed in Xenopus oocytes. Soc Neurosci 1996;22:1780 (abstr.).
40. Mahnir V.M., Lin B., Prokai-Tatrai K., Kem W.R. Pharmacokinetics and urinary excretion of DMXBA (GTS-21), a compound enhancing cognition. Biopharm. Drug Disp. 19:1998;147-151.
41. Mahnir VM, Prokai L, Lin B, Prokai-Tatrai K, Soti F, Xue Fang C, Kem WR. Primary hepatic metabolites of the Alzheimer's drug candidate DMXBA (GTS-21): Structures, syntheses, chemical properties and interactions with brain nicotinic receptors (Submitted).
42. Marks M.J., Burch J.B., Collins A.C. Effects of chronic nicotine infusion on tolerance development and nicotinic receptors. J. Pharmacol. Exp. Ther. 226:1983;817-825.
43. Martin E.J., Panikar K.S., King M.A., Deyrup M., Hunter B., Wang G., Meyer E.M. Cytoprotective actions of 2,4-dimethoxybenzylidene anabaseine in differentiated PC12 cells and septal cholinergic cells. Drug Dev. Res. 31:1994;134-141.
44. Martin-Ruiz CM, Court JA, Molnar E, Lee M, Gotti C, Mamalaki A, Tsouloufis T, Tzartos S, Ballard C, Perry RH, Perry EK. α4 but not α3 and 7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimers disease, 1999, Huddinge Mtg. Abstr.
45. Meyer E.M., de Fiebre C.M., Hunter B.E., Simpkins C.E., Frauworth N., de Fiebre N.E. Effects of anabaseine-related analogs on rat brain nicotinic receptor binding and on avoidance behaviors. Drug Dev. Res. 31:1994;127-1344.
46. Meyer E.M., King M.A., Meyers C. Neuroprotective effects of 2,4-dimethoxybenzylidene anabaseine (DMXB) and tetrahydroaminoacridine (THA) in neocortices of nucleus basalis lesioned rats. Brain Res. 768:1998;49-56.
47. Meyer E.M., Kuryatov A., Gerzanich V., Lindstrom J., Papke R.L. Analysis of 3-(4-hydroxy, 2-methoxybenzylidene)anabaseine selectivity and activity at human and rat α7 nicotinic receptors. J. Pharmacol. Exp. Ther. 287:1998;918-925.
48. Meyer E.M., Tay E.T., Zoltewicz J.A., Meyers C., King M.A., Papke R.L., de Fiebre C.M. Neuroprotective and memory-related actions of novel α7 nicotinic agents with different mixed agonist/antagonist properties. J. Pharmacol. Exp. Ther. 284:1998;1026-1032.
49. Mule C., Choquet D., Korn H., Changeux J.-P. Calcium influx through nicotinic receptor in rat central neurons: its relevance to cellular recognition. Neuron. 8:1992;135-143.
50. 3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci. Lett. 72:1986;115-121.
51. O'Hara B.F., Wiler S.W., Cao V.H., Edgar D.M., Kem W.R., Heller H.C., Kilduff T.S. Phase-shifting effects of specific muscarinic and nicotinic agonists in golden hamsters. Soc. Neurosci. 24:(Abstr. 466.6):1998;1185.
52. Olale F., Gerzanich V., Kuryatov A., Wang F., Lindstrom J. Chronic nicotine exposure differentially affects the function of human α3, α4, and α7 neuronal nicotinic receptor subtypes. J. Pharmacol. Exp. Ther. 283:1997;675-683.
53. Orr-Urtreger A., Goldner F.M., Saeki M., Lorenzo E., Goldberg L., De Biasi M., Dani J.A., Patrick J.W., Beaudet A.L. Mice deficient in the α7 neuronal nicotinic acetylcholine receptor lack α-bungarotoxin binding sites and hippocampal fast nicotinic currents. J. Neurosci. 17:1999;9165-9171.
54. Papke R.L., de Fiebre C.M., Kem W.R., Meyer E.M. The subunit specific effects of novel anabaseine-derived nicotinic agents. Giacobini E., Becker R. Alzheimer Disease: Therapeutic Strategies. 1995;206-211 Birkhauser, Boston.
55. Papke RL, Bencherif M, Lippiello P. An evaluation of neuronal nicotinic acetylcholine receptor activation by quaternary nitrogen compounds indicates that choline is selective for the α7 subtype. Neurosci Lett 1996;213:201-204.
56. Plowchalk D.R., Anderson M.E., deBethizy J.D. A physiologically based pharmacokinetic model for nicotine disposition in the Sprague-Dawley rat. Toxicol. Appl. Pharmacol. 116:1992;177-188.
57. Radcliffe K.A., Dani J.A. Nicotinic stimulation produces multiple forms of increased glutamatergic synaptic transmission. J. Neurosci. 18:1998;7075-7083.
58. Rao T.S., Correa L.D., Reid R.T., Lloyd G.K. Evaluation of anti-nociceptive effects of neuronal nicotinic acetylcholine receptor (NAChR) ligands in the rat tail-flick assay. Neuropharmacology. 35:1996;393-405.
59. Reitstetter R., Lukas R.J., Gruener R. Dependence of nicotinic acetylcholine receptor recovery from desensitization on the duration of agonist exposure. J. Pharmacol. Exp. Ther. 289:1999;656-660.
60. Schroder H., Giacobini E., Wevers A., Birtsch C., Schutx U. Nicotinic receptors in Alzheimer's disease. Domino E.F. Brain Imaging of Nicotine and Tobacco Smoking. 1995;NPP Books, Ann Arbor, MI.
61. Shimohama S., Greenwald D.L., Shafron D.H., Akaika A., Maeda T., Kaneko S., Kimura J., Simpkins C.E., Day A.L., Meyer E.M. Nicotinic α7 receptors protect against glutamate neurotoxicity and neuronal ischemic damage. Brain Res. 779:1998;359-363.
62. Stevens K.E., Kem W.R., Mahnir V.M., Freedman R. Selective α7-nicotinic agonists normalize inhibition of auditory response in DBA mice. Psychopharmacology. 136:1998;320-327.
63. Stitzel J.A., Banchette J.M., Collins A.C. Sensitivity to the seizure-inducing effects of nicotine is associated with strain-specific variants of the α5 and α7 nicotinic receptor subunit genes. J. Pharmacol. Exp. Ther. 284:1998;1104-1111.
64. Sugaya K., Giacobini E., Chiappinelli V.A. Nicotinic acetylcholine receptor subtypes in human frontal cortex; changes in Alzheimer's disease. J. Neurosci. Res. 27:1990;349-359.
65. Summers K., Kem W.R., Giacobini E. Nicotinic agonist modulation of neurotransmitter levels in the rat frontoparietal cortex. Jpn. J. Pharmacol. 74:1997;139-146.
66. Tani Y., Saito K., Imoto M., Ohno T. Pharmacological characterization of nicotinic receptor-mediated acetylcholine release in rat brain- an in vivo microdialysis study. Eur. J. Pharmacol. 35:1998;181-188.
67. Trachsel L., Heller H.C., Miller J.D. Nicotine phase-advances the circadian neuronal activity rhythm in rat suprachiasmatic nuclei explants. Neuroscience. 65:1995;797-803.
68. van Haaren F, Anderson KG, Haworth S, Kem WR. GTS-21, a mixed nicotinic receptor agonist/antagonist, does not affect the nicotine cue. Pharmacol Biochem Behav 1999;64:439-444.
69. Whitehouse P.J., Martino A.M., Antuono P.G., Lowenstein P.R., Coyle J.T., Price D.L., Kellar K.J. Nicotinic acetylcholine binding in Alzheimer's disease. Brain Res. 371:1986;146-151.
70. Woodruff-Pak D.S. Evaluation of cognition-enhancing drugs: utility of the model system of eyeblink conditioning. CNS Rev. 1:1995;107-128.
71. Woodruff-Pak D.S., Li Y.-T., Kazmi A., Kem W.R. Nicotinic cholinergic system involvement in eyeblink classical conditioning in rabbits. Behav. Neurosci. 108:1994;486-493.
72. Woodruff-Pak D.S., Li Y.-T., Kem W.R. A nicotinic receptor agonist (GTS-21), eyeblink classical conditioning, and nicotinic receptor binding in rabbit brain. Brain Res. 645:1994;309-317.
73. Yamamoto J, Kasahara N, Nanri M, Matsuura N, Morita F. Pharmacological and toxicological profiles of GTS-21, a novel nicotinic agonist for the treatment of Alzheimer's disease, Proc. 6th Intern. Conf. Alzheim. Dis., Amsterdam, 1998 (Abstr. 1083), Neurobiol Aging 19;S182.
74. Yamamoto J, Kasahara N, Nanri M, Matsuura N, Morita F. Pharmacological and toxicological profiles of GTS-21, a novel nicotinic agonist for the treatment of Alzheimer's disease, Proc. 6th Intern. Conf. Alzheim. Dis., Amsterdam, 1998 (Abstr. 1083), Neurobiol Aging 19;S182.
75. Young R.C., Mitchell R.C., Brown T.H., Ganellin C.R., Griffiths R., Jones M., Rana K.K., Saunders D., Smith I.R., Sore N.E., Wilks T.J. Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. J. Med. Chem. 31:1988;656-671.
76. Zhang X, Miao H, Nordberg A. Depressed expression of nicotinic receptors by chronic treatment with B-amyloid (25-35) in PC12 cells, Proc. 6th Intern. Conf. Alzh. Dis., Amsterdam, 1998 (Abstr. 175), Neurobiol Aging S42.
77. Zhang X, Miao H, Nordberg A. Depressed expression of nicotinic receptors by chronic treatment with B-amyloid (25-35) in PC12 cells, Proc. 6th Intern. Conf. Alzh. Dis., Amsterdam, 1998 (Abstr. 175), Neurobiol Aging S42.
78. Zoltewicz J.A., Prokai-Tatrai K., Bloom L.B., Kem W.R. Long range transmission of polar effects of cholinergic 3-arylideneanabaseines. Conformations calculated by molecular modelling. Heterocycles. 35:1993;171-179.